Aflac (AFL) FY2025 Earnings Quality Report

Grade: B — Generally Healthy, Minor Concerns

Framework: Financial-sector metrics (benefit ratio, ROE, investment portfolio quality, capital return) + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-25, FY ended December 31, 2025) + Yahoo Finance

Auditor: KPMG LLP — Unqualified opinion (PCAOB Firm ID 185, located in Atlanta, Georgia)

Note: Beneish M-Score and Altman Z-Score are not applicable to life insurance companies due to fundamentally different financial statement structures.

One-line verdict: Aflac remains a cash-generating machine anchored by its dominant Japanese supplemental insurance franchise, but FY2025 showed stress. Total revenues fell 9.3% to $17.2 billion, driven by $572 million in net investment losses versus $1.3 billion in gains the prior year. Net earnings dropped to $3.6 billion ($6.82/diluted share) from $5.4 billion ($9.63). The adjusted ROE excluding foreign currency was 17.6%, and the company repurchased $3.5 billion of shares. The screening engine flagged CFFO trailing net income for three consecutive years — a pattern that, while explainable for a life insurer with long-duration liabilities, warrants monitoring. A cybersecurity incident in June 2025 resulted in data exfiltration of customer information.

Business Structure: Japan Drives Everything

Per the 10-K: "The Company's insurance business consists of two reporting segments: Aflac Japan and Aflac U.S." Aflac Japan is described as "the principal contributor to the Parent Company's consolidated earnings and the largest insurer in Japan in terms of cancer and medical (third sector insurance products) policies in force."

This Japan dependency creates significant currency exposure. The average yen/dollar exchange rate was 149.32 in 2025, 1.1% stronger than 150.97 in 2024. The filing notes that a stronger yen "positively impacted adjusted earnings per diluted share by $.04."

Aflac U.S. markets supplemental insurance at the worksite, with approximately 5,300 agents actively producing business weekly. The company is expanding into direct-to-consumer digital distribution.

Revenue Decline: Investment Losses, Not Operating Deterioration

The 9.3% revenue decline requires decomposition:

The $572 million investment loss in 2025 included: $467 million from derivative and FX losses, $191 million increase in credit loss allowances, $6 million in impairments — partially offset by $72 million gain on equity securities and $20 million from sales/redemptions.

Operating performance was far more stable than the headline revenue decline suggests. This is a classic life-insurer pattern where investment portfolio mark-to-market creates earnings volatility that does not reflect underwriting quality.

Capital Strength and Shareholder Returns

The gap between GAAP book value ($56.85) and adjusted book value excluding FX ($42.66) reflects the embedded unrealized gains/losses in the investment portfolio and FX translation effects from the massive Japanese yen-denominated balance sheet.

Cash reserves of $70.4 billion against debt of $8.4 billion provide extraordinary liquidity — though much of this cash is held within regulated insurance subsidiaries and cannot be freely upstreamed to the parent.

The 18-Point Screening

Revenue & Cash Flow Quality

C1 is a structural issue, not manipulation. For a life insurer with long-duration policies, CFFO can systematically trail net income due to the timing of premium collection (upfront) versus claims payment (years later), combined with investment income recognition patterns. The CFFO/NI ratio of 0.70 in FY2025 is within normal range for a supplemental life insurer. The screening engine's F grade is overridden here because this pattern is structural to the business model, not indicative of earnings manipulation.

Balance Sheet

Manipulation Score

Key Risks from the 10-K

1. Cybersecurity Incident — Data Exfiltration

The 10-K discloses: "The Company identified an incident involving unauthorized access to a limited number of its systems in the U.S. on June 12, 2025." The filing states the company "contained the unauthorized access within hours" and systems "were not affected by ransomware." However, the company "is aware of the exfiltration of certain data including claims information, health information, social security numbers and/or other personal information." This creates regulatory, litigation, and reputational risk. The filing notes class action lawsuits have been filed.

2. Japan Regulatory and Demographic Risk

Aflac Japan operates under Japanese regulatory oversight where "minimum loss ratio requirements" and restrictions on premium rates apply. Japan's aging and declining population creates long-term headwinds for policy growth, even as it may increase claims frequency for cancer and medical products.

3. Benefit Ratio Scrutiny

The filing notes potential regulatory attention to "the low level of Aflac U.S. benefit ratios in recent financial periods." If regulators mandate higher loss ratios, it would directly compress margins on the U.S. supplemental insurance book.

4. Investment Portfolio Credit Risk

The filing emphasizes: "Any expected or sustained credit deterioration of the Company's investments will negatively impact the Company's net income and capital position." The $191 million increase in credit loss allowances in 2025 signals early stress. Aflac Japan has regulatory requirements for recognizing impairments that "could be triggered by credit-related losses, which may be different from U.S. GAAP."

Financial-Sector Grade Assessment

Grade: B. Aflac's franchise quality is undeniable — zero goodwill, dominant market position in Japan, consistent capital return. The downgrade from A reflects: (1) CFFO trailing net income for three consecutive years, which while structural deserves monitoring; (2) the $1.9 billion swing in investment results that drove the revenue decline; and (3) the cybersecurity incident creating unknown tail risk. The adjusted ROE of 17.6% and aggressive buyback program ($3.5B) confirm the underlying business remains strong.

**Disclaimer**: This report is based on Aflac's FY2025 10-K filed with SEC EDGAR on February 25, 2026. This is NOT investment advice.

Data: SEC EDGAR 10-K + Yahoo Finance

Auditor: KPMG LLP (Unqualified opinion, PCAOB Firm ID 185)

Fiscal year ended: December 31, 2025